282 related articles for article (PubMed ID: 35288464)
1. T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.
Morton LT; Wachsmann TLA; Meeuwsen MH; Wouters AK; Remst DFG; van Loenen MM; Falkenburg JHF; Heemskerk MHM
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288464
[TBL] [Abstract][Full Text] [Related]
2. Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence.
van Hees EP; Morton LT; Remst DFG; Wouters AK; Van den Eynde A; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2024; 15():1368290. PubMed ID: 38690288
[TBL] [Abstract][Full Text] [Related]
3. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
Jahn L; Hombrink P; Hagedoorn RS; Kester MG; van der Steen DM; Rodriguez T; Pentcheva-Hoang T; de Ru AH; Schoonakker MP; Meeuwsen MH; Griffioen M; van Veelen PA; Falkenburg JH; Heemskerk MH
Blood; 2017 Mar; 129(10):1284-1295. PubMed ID: 28053195
[TBL] [Abstract][Full Text] [Related]
4. HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for "Off-the-Shelf" Immunotherapy.
Hoerster K; Uhrberg M; Wiek C; Horn PA; Hanenberg H; Heinrichs S
Front Immunol; 2020; 11():586168. PubMed ID: 33584651
[TBL] [Abstract][Full Text] [Related]
5. Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells.
Falk CS; Steinle A; Schendel DJ
J Exp Med; 1995 Oct; 182(4):1005-18. PubMed ID: 7561674
[TBL] [Abstract][Full Text] [Related]
6. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
7. The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR alpha/beta-mediated recognition.
Pietra G; Romagnani C; Falco M; Vitale M; Castriconi R; Pende D; Millo E; Anfossi S; Biassoni R; Moretta L; Mingari MC
Eur J Immunol; 2001 Dec; 31(12):3687-93. PubMed ID: 11745389
[TBL] [Abstract][Full Text] [Related]
8. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis.
Guo Y; Xu B; Wu Z; Bo J; Tong C; Chen D; Wang J; Wang H; Wang Y; Han W
Eur J Immunol; 2021 Oct; 51(10):2513-2521. PubMed ID: 34323289
[TBL] [Abstract][Full Text] [Related]
9. Cytolytic T lymphocytes displaying natural killer (NK)-like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production.
Mingari MC; Vitale C; Cambiaggi A; Schiavetti F; Melioli G; Ferrini S; Poggi A
Int Immunol; 1995 Apr; 7(4):697-703. PubMed ID: 7547697
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.
Romanski A; Bug G; Becker S; Kampfmann M; Seifried E; Hoelzer D; Ottmann OG; Tonn T
Exp Hematol; 2005 Mar; 33(3):344-52. PubMed ID: 15730858
[TBL] [Abstract][Full Text] [Related]
12. Natural killer (NK)-cell function and antileukemic activity of a large population of CD3+/CD8+ T cells expressing NK receptors for major histocompatibility complex class I after "three-loci" HLA-incompatible bone marrow transplantation.
Albi N; Ruggeri L; Aversa F; Merigiola C; Tosti A; Tognellini R; Grossi CE; Martelli MF; Velardi A
Blood; 1996 May; 87(9):3993-4000. PubMed ID: 8611732
[TBL] [Abstract][Full Text] [Related]
13. Natural killer (NK)-like cytotoxic activity of allospecific T cell receptor-gamma,delta+ T cell clones. Distinct receptor-ligand interactions mediate NK-like and allospecific cytotoxicity.
Koide J; Rivas A; Engleman EG
J Immunol; 1989 Jun; 142(12):4161-8. PubMed ID: 2470816
[TBL] [Abstract][Full Text] [Related]
14. Combination of Expanded Allogeneic NK Cells and T Cell-Based Immunotherapy Exert Enhanced Antitumor Effects.
Wang X; Yang X; Wang Y; Chen Y; Yang Y; Shang S; Wang W; Wang Y
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612246
[TBL] [Abstract][Full Text] [Related]
15. TCR-independent cytokine stimulation induces non-MHC-restricted T cell activity and is negatively regulated by HLA class I.
von Geldern M; Simm B; Braun M; Weiss EH; Schendel DJ; Falk CS
Eur J Immunol; 2006 Sep; 36(9):2347-58. PubMed ID: 16909431
[TBL] [Abstract][Full Text] [Related]
16. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
[TBL] [Abstract][Full Text] [Related]
17. Innate-like NKp30
Correia MP; Stojanovic A; Wels WS; Cerwenka A
Oncoimmunology; 2021; 10(1):1973783. PubMed ID: 35036073
[TBL] [Abstract][Full Text] [Related]
18. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G.
Maki G; Hayes GM; Naji A; Tyler T; Carosella ED; Rouas-Freiss N; Gregory SA
Leukemia; 2008 May; 22(5):998-1006. PubMed ID: 18288133
[TBL] [Abstract][Full Text] [Related]
19. [NK-like cytotoxicity of allospecific gamma delta TCR+ T cell clones].
Koide J
Hum Cell; 1990 Oct; 3(3):220-5. PubMed ID: 1706201
[TBL] [Abstract][Full Text] [Related]
20. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer.
Parlar A; Sayitoglu EC; Ozkazanc D; Georgoudaki AM; Pamukcu C; Aras M; Josey BJ; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Duru AD; Sutlu T
Eur J Immunol; 2019 Aug; 49(8):1278-1290. PubMed ID: 31054264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
